03748nam 22006855 450 991029829430332120251215215818.03-319-18518-710.1007/978-3-319-18518-7(CKB)3710000000402838(EBL)2096709(SSID)ssj0001500646(PQKBManifestationID)11927799(PQKBTitleCode)TC0001500646(PQKBWorkID)11519884(PQKB)11533867(DE-He213)978-3-319-18518-7(MiAaPQ)EBC2096709(PPN)185489729(EXLCZ)99371000000040283820150422d2015 u| 0engur|n|---|||||txtccrThe Future of HIV-1 Therapeutics Resistance Is Futile? /edited by Bruce E. Torbett, David S. Goodsell, Douglas D. Richman1st ed. 2015.Cham :Springer International Publishing :Imprint: Springer,2015.1 online resource (257 p.)Current Topics in Microbiology and Immunology,0070-217X ;389Description based upon print version of record.3-319-18517-9 Includes bibliographical references and index.HIV Therapy ­ Looking Towards the Future -- Computational challenges of structure-based approaches applied to HIV -- Nucleocapsid Protein: A Desirable Target For Future Therapies Against HIV-1 -- HIV-1 integrase multimerization as a therapeutic target -- Targeting HIV transcription: The quest for a functional cure -- Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder -- HIV-1 Gag: An Emerging Target for Antiretroviral Therapy -- The Triple Threat of HIV-1 Protease Inhibitors -- Illustrations of the HIV Life Cycle.This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.Current Topics in Microbiology and Immunology,0070-217X ;389Drug resistanceVirologyInfectious diseasesDrug Resistancehttps://scigraph.springernature.com/ontologies/product-market-codes/B16020Virologyhttps://scigraph.springernature.com/ontologies/product-market-codes/B22003Infectious Diseaseshttps://scigraph.springernature.com/ontologies/product-market-codes/H33096Drug resistance.Virology.Infectious diseases.Drug Resistance.Virology.Infectious Diseases.610616.9616.9041616.9101Torbett Bruce E(Bruce Edward),edthttp://id.loc.gov/vocabulary/relators/edtGoodsell David S.edthttp://id.loc.gov/vocabulary/relators/edtRichman Douglas D.edthttp://id.loc.gov/vocabulary/relators/edtBOOK9910298294303321The Future of HIV-1 Therapeutics2494368UNINA